The circadian blood glucose profile of 15 unstable diabetics (4 IDDM, 11 NIDDM, 14-53 yrs.) was continuously monitored by the artificial endocrine pancreas (AEP, Biostator ®) with the conventional insulin therapy on the first day. On the next day, feedback control of 24-32 hours with the AEP was performed on each subject. Based on the data obtained, the patients received a new insulin regimen from the third day, consisting of two daily injections of a mixture of short-acting insulin (s.a.-I) and intermediate acting insulin (i.m.a.-I), 45-60 min. before meals. The dose of new insulin regimen was matched to about 60% of infused insulin dose with the AEP. The diurnal blood glucose profile of 6 subjects (2 IDDM, 4 NIDDM) was monitored again one month later.
1) The mean amplitude of glycemic excursions (MAGE) of 5 highly unstable (HU) diabetics was 187±14 mg/dl (mean±SD) and that of 10 moderately unstable (MU) diabetics was 138±13 mg/dl. There was a negative correlation between the sum of serum CPR during 50 gOGTT (ECPR) and the MAGE (r=-0.61, p<0.05).
2) The M-values before, during feedback control, and one month later were 66.6±26.6, 10.8± 4.1, 23.1±5.5 respectively. Each of the mean blood glucose concentrations (MBG) was 208±33mg/dl, 108±13 mg/dl, 122±27 mg/dl and the MAGE was 154±26 mg/dl, 65±16 mg/dl, 105±21 mg/dl respectively. The M-values, MBG and MAGE decreased significantly during feedback control and one month later, compared with those values obtained before feedback control. (p<0.001). However, the MAGE of 4 of 6 subjects did not remain in a stable range (<80 mg/dl), after 1 month. In those values obtained at each period, there was no significant difference between HU and MU subjects.
3) HbAt was 12.5±2.0% before feedback control, 11.2±1.8% one month later, 9.3±1.3% two months later and 9.2 + 1.2% four months later. The change of insulin dosage and the timing of injection caused a noticeable decrease in HbAI levels 1-4 months after feedback control (p<0.001).
4) The new insulin regimen was characterized by an increased proportion of s.a.-I in the daily dose from 26.4±12.1% to 40.3±11.5% after feedback control. (p<0.02). The rate of daily insulin dosage to the body weight increased from 0.56±0.18 U/kg (before) to 0.73±0.17 U/kg (after)(p<0.02). The new insulin regimen decreased hypoglycemic episodes.
Thus, we concluded that the AEP (Biostator ®) could be useful in the clinical management of unstable diabetics by providing a more precise estimate of the patient's insulin requirements, especially those of s. a.-I, leading to a better long-term control of blood glucose.
View full abstract